Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 8Unknown 6Recruiting 6Terminated 3Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 1328Neoplasms 998Carcinoma, Non-Small-Cell Lung 865Prostatic Neoplasms 730Colorectal Neoplasms 671Lung Neoplasms 553Leukemia, Myeloid, Acute 475Neoplasm Metastasis 427Pancreatic Neoplasms 426Carcinoma, Hepatocellular 407Ovarian Neoplasms 393Multiple Myeloma 393Stomach Neoplasms 383Recurrence 369Squamous Cell Carcinoma of Head and Neck 327Melanoma 295Uterine Cervical Neoplasms 288Brain Neoplasms 288Triple Negative Breast Neoplasms 273Glioblastoma 263Head and Neck Neoplasms 260Precursor Cell Lymphoblastic Leukemia-Lymphoma 256Endometrial Neoplasms 238Lymphoma 230Esophageal Neoplasms 226Rectal Neoplasms 224Sarcoma 213Carcinoma, Renal Cell 205Colonic Neoplasms 196Lymphoma, Large B-Cell, Diffuse 194

Interventions

testosterone enanthate 1disitamab vedotin 1Radiotherapy 1Metastasectomy 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Interventional × Castration-resistant Prostate Cancer × Clear all
NCT03522064 2026-04-23

HiTeCH

St Vincent's Hospital, Sydney

Phase 2 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT07259213 2026-04-01

RAD402

Radiopharm Theranostics, Ltd

Phase 1/2 Recruiting
73 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06636123 2026-01-27

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

Virginia Commonwealth University

Phase 1 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06585007 2024-09-05

MEDCARE

Universitaire Ziekenhuizen KU Leuven

Phase 3 Recruiting
246 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06343038 2024-08-14

PROGNOSTICS

University Hospital, Basel, Switzerland

Phase 1 Recruiting
25 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06227156 2024-05-23

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

RemeGen Co., Ltd.

Phase 2 Recruiting
40 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡